New potent anti-gram negative compounds from the myxobacteria Cor | 19144
Journal of Drug Metabolism & Toxicology

Journal of Drug Metabolism & Toxicology
Open Access

ISSN: 2157-7609


New potent anti-gram negative compounds from the myxobacteria Corallococcus coralloides

Joint Event on 31st Euro Global Summit and Expo on Vaccines & Vaccination & 4th World Congress and Exhibition on Antibiotics and Antibiotic Resistance

June 14-16, 2018 Barcelona, Spain

Won Gon Kim

Korea Research Institute of Bioscience and Biotechnology, South Korea

Posters & Accepted Abstracts: J Drug Metab Toxicol

Abstract :

Recently, infections caused by MDR Gram-negative bacteria has become a growing problem. There is an urgent need for new agents to treat infections caused by Gram-negative bacteria resistant to currently available agents. Myxobacteria are a group of Gram-negative bacteria that produce a diverse range of bioactive secondary metabolites. Myxobacteria have received attention as a source of novel anti-infective natural products. Our objective is to search for anti-Gram-negative metabolites from Korean myxobacteria. Two new potent anti-Gram negative compounds, coralmycins A(1) and B(2), were isolated from cultures of the myxobacteria Corallococcus coralloides M23, together with another derivative (3) that was identified as the very recently reported cystobactamid 919-2. Their structures including the relative stereochemistry were elucidated by interpretation of spectroscopic, optical rotation, and CD data. The antibacterial activity of 1 was most potent against Gramnegative pathogens, including Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumanii and Klebsiella pneumoniae, with MICs of 0.1â�?�?4 �?¼g/ml; these MICs were 4â�?�?10 and 40â�?�?100 times stronger than the antibacterial activities of 3 and 2, respectively. This result suggested that the �?²-methoxyasparagine unit and the hydroxy group of the benzoic acid unit were critical for antibacterial activity. Thus, this study indicated that coralmycin A has great potential for treatment of multidrugresistant bacteria, including Gram-negative bacteria.

Biography :

Won Gon Kim has completed his PhD from Seoul National University, South Korea, and Postdoctoral studies from NIH, USA. He is a Principal Research Scientist of Korea Research Institute of Bioscience and Biotechnology (KRIBB), South Korea. He has published more than 90 SCI papers in reputed journals.